In-House Training
For the release of biotechnological products, potency is a mandatory critical quality attribute that manufacturers must evaluate to ensure it conforms to specifications for releasing drug substance and drug product batches. Cell-based bioassays are commonly used to determine potency. While binding assays, including non-cell-based assays, can be considered during early clinical development, regulatory bodies expect that cell-based bioassays reflecting the mechanism of action of the biotherapeutic be developed and implemented during late clinical development. These assays should then be appropriately validated before performing the process performance qualification. This Master Class addresses common bioassay formats, as well as the development and validation of bioassays.
Use the proper terminology of bioassays and their validation
Know the major sources of information
Understand biological activity vs potency and purpose of bioassays
Understand parameters that could affect the outcome of bioassays
Implement appropriate approaches for cell line development, cell bank establishment and testing
Know-how to design bioassays, including: fitness for use, concept of relative potency, assay optimization, determination of standard curves, and statistical considerations
Master the validation of bioassays in accordance with pre-defined acceptance criteria
Check for robustness of bioassays
Provide examples of bioassay formats and case studies
Bioassay development scientists
Bioassay validation personnel
Stability scientists
QA/QC personnel
Regulatory CMC
CMC project managers
Bioassays and validation terminology
Regulatory guidelines and bibliography
What bioassays are and their purpose
Common bioassay formats and regulatory expectations for reflecting the mechanism of action of a biotherapeutic
Cell line development, cell bank establishment and testing
Design and development of bioassays, including assay parameters
Bioassay validation
Satistical considerations
Suitability testing
Analysis of bioassays
cases studies, including the replacement of in vivo assays with cell-based in vitro bioassays
Questions and answers
Please contact us at mylene.talabardon@biotechnologyconsultant.com